SRDX (Surmodics) Beneish M-Score: -2.95 (As of Jun. 25, 2026)

What is Surmodics Beneish M-Score?

Surmodics SRDX -0.01% 51 Beneish M-Score is -2.95 as of Jun. 25, 2026. GuruFocus rates SRDX with a GF Score™ of 51/100 and a GF Value™ of $32.10. The stock has 5 warning signs investors should review.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.95 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Surmodics's Beneish M-Score or its related term are showing as below:

SRDX' s Beneish M-Score Range Over the Past 10 Years
Min: -4.15 Med: -2.68 Max: -1.39
Current: -2.95

During the past 13 years, the highest Beneish M-Score of Surmodics was -1.39. The lowest was -4.15. And the median was -2.68.

Surmodics Beneish M-Score Related Terms

Surmodics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Surmodics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics Beneish M-Score Chart

Surmodics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Beneish M-Score

Get a 7-Day Free Trial

-2.87

-2.41

-2.80

-3.07

-2.83

Surmodics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25
Beneish M-Score	Get a 7-Day Free Trial															-2.45	-2.83	-3.11	-2.99	-2.95

SRDX vs CBLL, OFIX, LAB: Beneish M-Score Comparison

For the Medical Devices subindustry, Surmodics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surmodics Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Surmodics's Beneish M-Score falls into.

Save Embed

51GF Score

Surmodics Inc SRDX

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Surmodics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Surmodics for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.0402

0.528 * 0.9507

0.404 * 1.0461

0.892 * 0.9998

0.115 * 0.9308

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 1.1361

4.679 * -0.099422

0.327 * 1.0124

-2.95

This Year (Jun25) TTM:

Last Year (Jun24) TTM:

Total Receivables was $25.0 Mil.
Revenue was 29.567 + 28.085 + 29.922 + 33.227 = $120.8 Mil.
Gross Profit was 13.418 + 11.888 + 13.556 + 14.851 = $53.7 Mil.
Total Current Assets was $76.0 Mil.
Total Assets was $169.8 Mil.
Property, Plant and Equipment(Net PPE) was $25.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.5 Mil.
Selling, General, & Admin. Expense(SGA) was $62.5 Mil.
Total Current Liabilities was $19.4 Mil.
Long-Term Debt & Capital Lease Obligation was $31.6 Mil.
Net Income was -5.318 + -5.209 + -3.651 + -3.449 = $-17.6 Mil.
Non Operating Income was 0.177 + 0.183 + 0.419 + 0.36 = $1.1 Mil.
Cash Flow from Operations was 1.405 + 0.949 + -7.894 + 3.658 = $-1.9 Mil.

Total Receivables was $24.1 Mil.
Revenue was 30.341 + 31.958 + 30.552 + 27.97 = $120.8 Mil.
Gross Profit was 12.128 + 14.628 + 13.085 + 11.235 = $51.1 Mil.
Total Current Assets was $80.4 Mil.
Total Assets was $177.4 Mil.
Property, Plant and Equipment(Net PPE) was $28.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.7 Mil.
Selling, General, & Admin. Expense(SGA) was $55.1 Mil.
Total Current Liabilities was $20.2 Mil.
Long-Term Debt & Capital Lease Obligation was $32.4 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(25.022 / 120.801)	/	(24.058 / 120.821)
	=	0.207134	/	0.199121
	=	1.0402

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(51.076 / 120.821)	/	(53.713 / 120.801)
	=	0.422741	/	0.44464
	=	0.9507

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (75.994 + 25.234) / 169.822)	/	(1 - (80.356 + 28.552) / 177.413)
	=	0.403917	/	0.386133
	=	1.0461

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	120.801	/	120.821
	=	0.9998

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(8.712 / (8.712 + 28.552))	/	(8.464 / (8.464 + 25.234))
	=	0.233791	/	0.251172
	=	0.9308

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(62.548 / 120.801)	/	(55.064 / 120.821)
	=	0.517777	/	0.455749
	=	1.1361

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((31.558 + 19.441) / 169.822)	/	((32.432 + 20.196) / 177.413)
	=	0.300309	/	0.296641
	=	1.0124

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-17.627 - 1.139	-	-1.882)	/	169.822
	=	-0.099422

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Surmodics has a M-score of -2.95 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -2.95 mean?

Surmodics (SRDX) has a Beneish M-Score of -2.95 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Surmodics and its competitors.

Is Surmodics' Beneish M-Score too high?

Surmodics' current Beneish M-Score is -2.95. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.

How does Surmodics' Beneish M-Score compare to CBLL and OFIX?

Surmodics' Beneish M-Score of -2.95 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Medical Devices & Instruments company?

A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Surmodics and its competitors. Surmodics's current Beneish M-Score is -2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Surmodics stock overvalued right now?

Surmodics (SRDX) has a current Beneish M-Score of -2.95. The stock's GF Value™ is $32.10, compared to a current price of $42.98 — trading 33.9% above its estimated fair value. The current Beneish M-Score is -2.95. Surmodics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Surmodics (SRDX), the current Beneish M-Score is -2.95 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Surmodics (SRDX) Overvalued in 2026?

Based on GuruFocus' analysis, Surmodics stock appears to be overvalued. The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.

Key valuation signals for SRDX:

Beneish M-Score: -2.95
GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Surmodics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies CBLL OFIX LAB TCMD AVNS NPCE PACB BVS CTKB VREX ABT BSX SYK MDT XTER:SHL EW SZSE:300760 XAMS:PHIA STE DXCM

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website https://www.surmodics.com

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

51GF Score

Get the complete analysis for SRDX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98

Price

$32.10

GF Value

View SRDX Analysis

See Beneish M-Score data for all stocks →